The safety and efficacy of amrubicin in the treatment of previously untreated extensive-disease small-cell lung cancer: a meta-analysis

Autor:	Ji-Feng Wu, Jian-Jun Zhou, Meng-Li Wen, Li-Hui Hu, Xin-Ai Li
Rok vydání:	2019
Předmět:	0301 basic medicine Oncology medicine.medical_specialty Anthracycline medicine.medical_treatment law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Pharmacology (medical) Lung cancer Adverse effect Chemotherapy Leukopenia business.industry medicine.disease Regimen 030104 developmental biology 030220 oncology & carcinogenesis medicine.symptom business Amrubicin
Zdroj:	OncoTargets and Therapy. 12:5135-5142
ISSN:	1178-6930
Popis:	Background: Extensive-disease small-cell lung cancer (ED-SCLC) has been known to be rapid progression and relapse, despite highly sensitive to chemotherapy. Amrubicin (AMR), a third-generation synthetic anthracycline, was accepted as a feasible alternative compared with the standard first-line chemotherapy for previously untreated ED-SCLC. While, the efficacies of these amrubicin-based regimens are unsatisfactory. Aim: Our meta-analysis was performed to assess the efficacy and toxicity of first-line therapy comparing AMR and chemotherapy in patients with ED-SCLC. Methods: Electronic databases were searched for eligible trials updated on November 2018. Randomized-controlled trials assessing the efficacy and safety of AMR in ED-SCLC were included, of which the interested results were objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs). Results: A total of 6 randomized controlled trials were included in this analysis. There are no significant differences in OS (OR=1.03, 95% CI=0.66-1.60, P=0.91), PFS (OR=1.2, 95% CI=10.77-1.88, P=0.41) or ORR (OR=1.31, 95% CI=0.90-1.92, P=0.16) with AMR (OR=0.90, 95% CI=0.76-1.05, P=0.17). The most common treatment-related AEs in the AMR group are leukopenia (OR=3.13, 95% CI=1.22-7.99, P=0.02) and neutropenia (OR=3.25, 95% CI=1.38-7.65, P=0.007). Fatigue, anemia, nausea, vomiting, diarrhea the difference between the two groups had no statistical significance. Conclusion: The results of our analysis indicated that AMR therapy demonstrated non-inferiority to the standard first-line chemotherapy for previously untreated ED-SCLC. Whether it can be accepted as an alternative regimen to the standard first-line chemotherapy is still warranted.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::dd74fe2ab8545dfe91a095053ab1f7d4 https://doi.org/10.2147/ott.s200601 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.